We are studying a combination of tucatinib, capecitabine, and trastuzumab for patients with HER2-positive breast cancer that has spread to the meninges. The goal is to see if this treatment improves survival and quality of life.
Health conditions and diseases that the clinical trial is designed to study and treat.
HER2-amplified metastatic breast cancer with leptomeningeal metastases is a serious condition where breast cancer cells that overexpress the HER2 protein spread to the membranes surrounding the brain and spinal cord, often requiring specialized treatments like intrathecal therapy.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.